Principal Financial Group Inc. Decreases Stake in C.R. Bard, Inc. (BCR)
Principal Financial Group Inc. reduced its stake in C.R. Bard, Inc. (NYSE:BCR) by 1.1% during the first quarter, according to its most recent filing with the SEC. The fund owned 1,176,209 shares of the medical instruments supplier’s stock after selling 13,164 shares during the period. Principal Financial Group Inc. owned about 1.62% of C.R. Bard worth $292,335,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in BCR. ETRADE Capital Management LLC raised its position in C.R. Bard by 1.7% in the third quarter. ETRADE Capital Management LLC now owns 1,054 shares of the medical instruments supplier’s stock valued at $236,000 after buying an additional 18 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in C.R. Bard by 22.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 1,507 shares of the medical instruments supplier’s stock valued at $339,000 after buying an additional 276 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in C.R. Bard by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,215 shares of the medical instruments supplier’s stock worth $947,000 after buying an additional 20 shares during the period. Private Advisor Group LLC acquired a new stake in C.R. Bard during the fourth quarter worth $232,000. Finally, Dimensional Fund Advisors LP raised its stake in C.R. Bard by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 235,925 shares of the medical instruments supplier’s stock worth $53,003,000 after buying an additional 2,748 shares during the period. Institutional investors own 88.32% of the company’s stock.
Shares of C.R. Bard, Inc. (NYSE BCR) traded down 0.12% during trading on Friday, reaching $313.56. 728,015 shares of the company traded hands. The company has a market capitalization of $22.71 billion, a price-to-earnings ratio of 39.91 and a beta of 0.64. The stock’s 50 day moving average is $309.48 and its 200 day moving average is $257.26. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $315.29.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, topping the consensus estimate of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The company had revenue of $938.80 million for the quarter, compared to analyst estimates of $916.15 million. During the same quarter in the previous year, the company posted $2.34 earnings per share. The firm’s revenue was up 7.5% compared to the same quarter last year. On average, analysts forecast that C.R. Bard, Inc. will post $11.78 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be paid a $0.26 dividend. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is presently 13.21%.
A number of analysts recently weighed in on BCR shares. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $276.00 price objective for the company in a research note on Friday, March 3rd. BMO Capital Markets reaffirmed a “buy” rating and issued a $255.00 price objective on shares of C.R. Bard in a research note on Tuesday, April 11th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $237.00 price objective on shares of C.R. Bard in a research note on Monday, March 27th. Raymond James Financial, Inc. lowered shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research note on Wednesday, April 26th. Finally, Wells Fargo & Company lowered shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $265.62.
In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the business’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the sale, the vice president now directly owns 10,139 shares in the company, valued at $3,082,256. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.80% of the stock is owned by insiders.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.